Fondaparinux in pregnancy: Could it be a safe option? A review of the literature.

Abstract

During pregnancy thrombo-prophylaxis could be required in high risk women. If a severe allergic reaction to low-molecular-weight-heparin (LMWH) or a heparin-induced-thrombocytopenia (HIT) occurs, it's mandatory to stop the drug. Fondaparinux could be an effective option. In the present review, the maternal and pregnancy outcomes of 65 pregnancies in women using Fondaparinux were reported. It was well-tolerated and rate of pregnancy complications was similar to that observed in general population. Regarding congenital malformations, further studies are necessary to investigate the safety of the drug.

• Authors: S De Carolis, E di Pasquo, E Rossi, G Del Sordo, A Buonomo, D Schiavino, A Lanzone, V De Stefano
• Journal: Thrombosis research (Thromb Res) Vol. 135 Issue 6 Pg. 1049-51 (Jun 2015) ISSN: 1879-2472 [Electronic] United States
• PMID: 25912931 (Publication Type: Journal Article, Review)
• Copyright: Copyright © 2015 Elsevier Ltd. All rights reserved.

Chemical References

• Anticoagulants
• Heparin, Low-Molecular-Weight
• Polysaccharides
• Fondaparinux

Topics

• Anticoagulants (adverse effects, therapeutic use)
• Female
• Fondaparinux
• Heparin, Low-Molecular-Weight (therapeutic use)
• Humans
• Maternal Exposure
• Patient Safety
• Polysaccharides (adverse effects, therapeutic use)
• Pregnancy
• Pregnancy Complications, Cardiovascular (drug therapy)
• Risk
• Thrombocytopenia (chemically induced, prevention & control)
• Thrombosis (prevention & control)